A new life-saving genetic test for Spinal Muscular Atrophy (SMA) will be rolled out for every baby born in England, giving clinicians a vital opportunity to detect the rare but serious condition before symptoms emerge. The nationwide initiative, part of an evaluation programme, is set to begin later this year, with hundreds of thousands of babies expected to be screened.
SMA is a severe genetic condition that can significantly impair a baby's ability to sit, crawl, or walk. In its most severe forms, it can even affect breathing and swallowing. However, early diagnosis is paramount, as treatments administered before symptoms manifest can dramatically improve a child's quality of life and long-term health outcomes. The screening process involves a simple heel prick test, where a small blood sample is collected from the newborn shortly after birth.
The government has accelerated the rollout of the programme, with laboratories across England scheduled to begin testing for SMA from October 2026, three months earlier than initially planned. This commitment follows earlier calls to speed up the process. Health and Social Care Secretary James Murray highlighted the importance of the expansion, stating that no parent should witness their child losing essential abilities when earlier intervention could have made a difference. He also acknowledged the tireless efforts of campaigners who have advocated for increased awareness and screening for the condition.
The Department of Health and Social Care is actively seeking investment to fund the comprehensive rollout. Following a model successfully implemented in Scotland, which leveraged private sector funding, England plans to adopt a similar collaborative approach with partners to ensure the accelerated delivery of the programme. Campaigners, including Jesy Nelson, expressed immense pride and hope, noting that the rollout beginning in October and continuing throughout 2027 will provide future families with access to early diagnosis and the best possible outcomes.
Giles Lomax, Chief Executive Officer of Spinal Muscular Atrophy (SMA), echoed this sentiment, calling it a 'hugely important step forward' after years of advocacy by the SMA community. He emphasised that thousands of babies will benefit from earlier diagnosis and access to life-changing treatments, eliminating the 'postcode lottery' for a condition where every day without treatment can lead to irreversible loss of motor neurons. The full implementation, with all remaining six screening laboratories beginning screening by October 2027, demonstrates a clear commitment to making newborn screening universally available across England.